Lantheus Holdings (LNTH) Gross Margin (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Gross Margin of 61.2% for Q1 2026, down 257.0% year-over-year from 38.98% in Q1 2025, and up 3.35% quarter-over-quarter from 59.21% in Q4 2025.
Lantheus Holdings (LNTH) Gross Margin (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Gross Margin for 13 consecutive years, with 61.2% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 257.0% year-over-year to 61.2%; the TTM figure through Mar 2026 stood at 60.48% (down 356.0% YoY), while the FY2025 annual figure was 61.1%, down 333.0% from the prior year.
- Gross Margin grew to 61.2% in Q1 2026 per LNTH's latest filing, from 59.21% in the prior quarter.
- Across five years, Gross Margin topped out at 1532.46% in Q4 2023 and bottomed at 25.63% in Q1 2023.
- Historically, Gross Margin has averaged 146.81% across 5 years, with a median of 62.99% in 2023.
- Annual changes were most pronounced in 2023 — Gross Margin soared 146894 bps — and 2024, when it plunged 146891 bps.
- Lantheus Holdings' Gross Margin stood at 63.52% in 2022, then surged by 2312 bps to 1532.46% in 2023, then slumped by 96 bps to 63.55% in 2024, then fell by 7 bps to 59.21% in 2025, then gained by 3 bps to 61.2% in 2026.
- Business Quant data shows LNTH's Gross Margin at 61.2% in Q1 2026, 59.21% in Q4 2025, and 57.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 62.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.30% |
| Mar 31, 2026 | 61.20% |
| Dec 31, 2025 | 59.21% |
| Sep 30, 2025 | 57.91% |
| Jun 30, 2025 | 63.75% |
| Mar 31, 2025 | 63.77% |
| Dec 31, 2024 | 63.55% |
| Sep 30, 2024 | 63.93% |
| Jun 30, 2024 | 64.90% |
| Mar 31, 2024 | 65.37% |
| Dec 31, 2023 | 1,532.46% |
| Sep 30, 2023 | 62.50% |
| Jun 30, 2023 | 62.99% |
| Mar 31, 2023 | 25.63% |
| Dec 31, 2022 | 63.52% |
| Sep 30, 2022 | 61.61% |
| Jun 30, 2022 | 61.70% |
| Mar 31, 2022 | 61.79% |
| Dec 31, 2021 | 44.70% |
| Sep 30, 2021 | 41.80% |